Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA ‘Public Health’ Approach To Opioids May Open Up Pricing Debates

Jan 22 2020

• By Michael McCaughan

Large US American flag on sailboat off the coast of California

Related Content

Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues

Jan 20 2020

‘Real World’ Opioid Abuse Data On OxyContin Again Under Review At US FDA

Jan 22 2020

Esteve’s Tramadol/Celecoxib: US FDA Cites No Major Concerns, But Also No Advantages

Jan 14 2020

Related Companies

Nektar Therapeutics

Intellipharmaceutics International Inc.

Esteve Pharmaceuticals, S.A.

Additional Topics

United States Pricing Debate Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window